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S U M M A R Y
Objectives: To study the resurgence of inﬂuenza B/Yam in Taiwan and summarize clinical ﬁndings of
inﬂuenza B-associated complications among hospitalized patients, in particular the link between clinical
and molecular epidemiologic characteristics.
Methods: Clinical information and isolates were collected through the national surveillance system of
the Taiwan Centers for Disease Control. Potential risk factors associated with severe illness were
analyzed. Antigenic and genetic analysis of representative hemagglutinin (HA) nucleotide sequences
was performed.
Results: Of 326 patients admitted to the intensive care unit (ICU), 63.2% were aged 18 years or 65
years and 12.9% were adults aged 19–49 years. Most of the cases had underlying medical conditions
before admission, and more fatal cases had chronic medical conditions than those who convalesced in
the ICU. Results of the phylogenetic analysis showed that the majority of isolates from fatal cases in
Taiwan were in group 2 (represented by B/Massachusetts/2/2012-like) rather than group 3, which was
the predominant group of strains circulating in other Asian countries.
Conclusions: Our ﬁndings suggest a regional trend of inﬂuenza B viruses and showed that new
phylogenetic lineages and antigenic variants emerging in neighboring countries were likely to be the
progenitors of the epidemic strains in the following seasons.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Inﬂuenza B viruses are some of the most active pathogens in
Taiwan and cause signiﬁcant morbidity and mortality.1,2 Historical
and contemporary descriptions of inﬂuenza severity have charac-
teristically focused on seasonal or pandemic inﬂuenza A viruses.3–5
However, inﬂuenza B virus infection causes rates of hospitalization
and inﬂuenza-associated complications similar to seasonal* Corresponding author. Tel.: +886 2 27850513 ext. 886; fax: +886 2 27853944.
E-mail address: jeffy320@cdc.gov.tw (J.-H. Lin).
http://dx.doi.org/10.1016/j.ijid.2014.02.017
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).inﬂuenza A virus infection and accounts for a substantial
percentage of all inﬂuenza-related hospitalizations and deaths.6,7
There were four inﬂuenza B predominant ﬂu seasons in the past
decade, in 2004–2005 (both B/Yam-like and B/Vic-like strains co-
circulating), 2006–2007 (B/Vic-like strain), 2010 (summer ﬂu; B/
Yam-like strain), and 2010–2011 (B/Vic-like strain). During the
2011–2012 season, annual inﬂuenza activity surveyed by the
Taiwan Centers for Disease Control (CDC) showed an island-wide
increased activity of inﬂuenza B virus (Yamagata lineage, B/Yam)
compared to that seasonally expected, and there were more severe
and fatal cases compared to previous years. As opposed to
inﬂuenza A viruses, inﬂuenza B viruses do not undergo antigenic
shift or cause pandemics.8–10ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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infections in Taiwan and other Asian countries. A recent study
suggested that vaccine-mismatched inﬂuenza B viruses in Taiwan
during the 2011–2012 season contributed to large epidemic
outcomes of inﬂuenza B infection and that the estimated inﬂuenza
vaccine effectiveness is age-related.11 In this report, we describe
the resurgence of inﬂuenza B/Yam in Taiwan, summarize clinical
ﬁndings of inﬂuenza-associated complications among hospitalized
patients during the epidemics in the 2011–2012 ﬂu season, and
examine the characteristics of the antigenic and genetic variances
of inﬂuenza B viruses, in particular the link between clinical and
molecular epidemiologic characteristics within the inﬂuenza-
associated complications among hospitalized patients.
2. Materials and methods
2.1. Case patients and data collection
Complicated inﬂuenza infection is a national notiﬁable disease in
Taiwan. To reinforce the efﬁciency of surveillance, the Taiwan CDC
established a sentinel surveillance system across Taiwan. Cases were
deﬁned as persons hospitalized for a community-onset, laboratory-
conﬁrmed inﬂuenza infection. According to the Communicable
Disease Control Act, all complicated cases of suspected inﬂuenza
must be reported and a specimen collected and sent to the Taiwan
CDC through the National Notiﬁable Disease Surveillance System.
Case patients were admitted to a surveillance-area medical center
during the inﬂuenza season and within 14 days of a positive
inﬂuenza test. Respiratory secretions from throat swabs, nasopha-
ryngeal aspirate, or bronchoalveolar lavage were collected from
patients who were suspected of having an inﬂuenza infection.
Laboratory conﬁrmation of inﬂuenza was by viral culture, immu-
noﬂuorescence antibody staining, reverse transcriptase PCR (RT-
PCR), or a commercially available rapid diagnostic test. Conﬁrmed
cases were classiﬁed as having a severe illness if they were admitted
to an intensive care unit (ICU) or died. Data extraction was
performed by physicians to collect demographic characteristics,
underlying medical conditions, treatments, and outcomes.
2.2. Virological investigation
Initial phylogenetic trees were inferred with the maximum
likelihood (ML) and neighbor-joining (NJ) methods implemented
in PHYML 3.0 and MEGA 5, respectively,12,13 using the transition/
transversion ratio and alpha parameter of the gamma distribution
estimated by maximum likelihood with TREE-PUZZLE software.14
The genomic sequences of vaccine strains recommended by the
World Health Organization (WHO) were used as referenceTable 1
Clinical characteristics of fatal cases and patients with severe complications of inﬂuen
Symptoms Fatal, n = 87 
n % 
Fever, >38 8C 62 71.3 
Cough 49 56.3 
Chest X-ray-conﬁrmed pneumonia 45 51.7 
ARDS 44 50.6 
Shortness of breath 39 44.8 
Myalgia 10 11.5 
Sudden onset of high fever 8 9.2 
Encephalitis 1 1.1 
Sore throat 10 11.4 
Encephalopathy 1 1.1 
Lower respiratory tract infection 3 3.4 
Othera 9 10.3 
ICU, intensive care unit; ARDS, acute respiratory distress syndrome.
a Other symptoms include diarrhea, abdominal pain, chest pain, hypotension, fatigusequences and were retrieved from the National Center for
Biotechnology Information (NCBI) Inﬂuenza Virus Resource
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) and the
Global Initiative on sharing All Inﬂuenza Data (GISAID, http://
www.gisaid.org). Antigenic characterization of inﬂuenza was
based on the ability of the virus to agglutinate guinea pig
erythrocytes and the capacity of antibodies to interfere with
hemagglutination. Viruses were characterized by hemagglutina-
tion inhibition (HI) assays as described elsewhere,15–17 using post-
infection ferret antisera.
2.3. Statistical analysis
Demographic variables and clinical characteristics were com-
pared using multi-way contingency tables and computing Chi-
square values. Fisher’s exact test was used for variables with n  5.
Two-sided t-tests were used to compare numerical data. For all
tests, p < 0.05 was considered signiﬁcant.
2.4. Ethical approval
This study was approved by the Institutional Review Board of
the Centers for Disease Control, Taiwan (No. 101006).
3. Results
From November 2011 to February 2012, a total of 2132 cases
with suspected inﬂuenza complications were reported to the
Taiwan CDC; 1138 of them were matched and conﬁrmed with the
inﬂuenza-associated complications criteria. Of these conﬁrmed
cases, 390 were admitted to hospitals; 326 (83.6%) of them had an
inﬂuenza B virus infection and the other 64 were inﬂuenza A-
positive. Among these hospitalized case patients with inﬂuenza B
infection, 325 of 326 were admitted to the ICU and 87 died during
hospitalization. The mean interval from onset to death was
18.40  1.82 days. The most common clinical manifestations were
cough (56.4%), fever >38 8C (72.4%), acute respiratory distress
syndrome (ARDS) (49.4%), shortness of breath (42.6%), and chest X-
ray-conﬁrmed pneumonia (54.0%) (Table 1).
The majority of cases were diagnosed by virus isolation. The
positive rate of the antigen assay was 67.2% compared with real-
time RT-PCR. Of the 326 inﬂuenza B-positive patients for whom
demographic information was obtained from the medical charts,
206 (63.2%) were aged 18 years or 65 years and 42 (12.9%) were
adults aged 19–49 years. The median age of the patients was 63.3
years (range 1–102 years) and the number of case patients in each
age group increased with increasing age, except the 19–24 years
age group (Table 2).za B virus infection in Taiwan, 2011–2012
ICU, n = 239 Total, n = 326
n % n %
174 72.8 236 72.4
135 56.5 184 56.4
131 54.8 176 54.0
117 49.0 161 49.4
100 41.8 139 42.6
32 13.4 42 12.9
38 15.9 46 14.1
6 2.5 7 2.1
37 15.5 47 14.4
6 2.5 7 2.1
5 2.1 8 2.5
45 18.8 54 16.1
e, nausea, drowsiness, and rhinorrhea.
Table 2
Demographic characteristics and disease outcomes of hospitalized patients in the inﬂuenza B outbreak in Taiwan, 2011–2012
Age, years Fatal, n = 87 ICU, n = 239 Total, n = 326
Male Female Male Female
n % n % n % n % n %
0–4 0 0 3 8.3 8 5.9 6 5.9 17 5.2
5–18 5 9.8 3 8.3 20 14.6 8 7.8 36 11.0
19–24 0 0 0 0 1 0.7 2 2.0 3 0.9
25–49a 2 3.9 3 8.3 17 12.4 17 16.7 39 12.0
50–64 18 35.3 8 22.2 30 21.9 23 22.5 78 23.9
65+ 26 51.0 19 52.9 61 44.5 46 45.1 153 47.0
Total 51 100 36 100 137 100 102 100 326 100
Median age 71.4 62.0 63.3
Age range 0–102 0–95 0–102
ICU, intensive care unit.
a p < 0.05.
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condition before admission, and more fatal cases had a chronic
medical condition, particularly hypertension (p < 0.05), than did
those who convalesced in the ICU (85.1% vs. 72.4%; Table 3).
Pneumonia was reported at a similar frequency in patients with
and without an underlying medical condition (78.4% vs. 72.7%),
including asthma or COPD (9.7% vs. 11.3%), and not many had a
neurological disease (2.9% vs. 2.0%), such as cerebral palsy or
developmental delay.
Nearly all fatal cases (97.7%) received antiviral treatment during
their illness, and the median interval before death was 14 days
(interquartile range 2–52 days). Four (36.3%) case patients in the
younger age group (age 18 years; 0.9, 1.6, 6.7, and 7.0 years old,
respectively) died within 2–3 days after onset; this was three-fold
higher than in the elderly group (age 65 years) (Table 4). The causes
of death were septic shock in 35 patients, pneumonia and respiratory
failure in 23 patients, pneumonia and multiple organ failure in
11 patients, and cardiopulmonary failure in 11 patients (Table 5).Table 3
Presence of underlying medical conditions in case patients hospitalized with inﬂu
Fatal
n = 74 of 87a
n 
Underlying diseases
Hypertensionb 39 
Diabetes mellitus 24 
Chronic renal failure, ESRD 10 
Hyperlipidemia 2 
Cancer 6 
COPD 8 
Coronary artery disease 2 
Old CVA 5 
Cerebral palsy 0 
HCVD 3 
Asthma 3 
TB 1 
Parkinson’s disease with dementia 6 
Hepatitis (B, C)-related liver diseasesb 7 
Congestive heart failure 3 
Atrial ﬁbrillation 2 
Ischemic heart disease 0 
Gouty arthritis 2 
Anemia 2 
BPH 1 
Schizophrenia 0 
SLE 0 
ICU, intensive care unit; ESRD, end-stage renal disease; COPD, chronic obstruct
cardiovascular disease; TB, tuberculosis; BPH, benign prostatic hyperplasia; SLE, s
a Number of case patients with information about underlying conditions.
b p < 0.05.Results of the antigenic analysis of all 326 inﬂuenza B isolates,
as well as genetic analysis of 55 representative hemagglutinin (HA)
nucleotide sequences, indicated that the Taiwanese inﬂuenza B
viruses during the 2011–2012 season were related to the Yamagata
lineage, and most of them (51 of 55 analyzed) were genetically
closely related to B/Brisbane/3/07. All lacked antigenic cross-
reactivity with the inﬂuenza B vaccine strain (B/Brisbane/60/2008-
like, Victoria lineage) used in Taiwan throughout this epidemic.
The weekly distribution of Taiwanese inﬂuenza B virus isolates
in 2001–2012 is shown in Figure 1A, together with the rate of
culture-conﬁrmed cases. The antigenic variability of an inﬂuenza
virus HA molecule occurs mainly in the HA1 domain,18 thus the
nucleotide sequences encoding the HA1 peptide (positions 1–
1140) in the 2011–2012 season inﬂuenza B viruses circulating in
Taiwan were determined. Phylogenetic analyses of the HA1
sequence data generated from representative viruses are shown
in Figure 1B and the tree topology of the neuraminidase (NA) gene
is shown in the Supplementary Material Figure S1.enza B infection in Taiwan, 2011–2012
ICU
n = 173 of 239a
% n %
52.7 69 39.9
32.4 57 32.9
13.5 22 12.7
2.7 9 5.2
8.1 7 4.0
10.8 16 9.2
2.7 17 9.8
6.8 12 6.9
0 5 2.9
4.1 10 5.8
4.1 7 4.0
1.4 8 4.6
8.1 9 5.2
9.5 4 2.3
4.1 14 8.1
2.7 7 4.0
0 4 2.3
2.7 1 0.6
2.7 0 0
1.4 7 4.0
0 3 1.7
0 2 1.2
ive pulmonary disease; CVA, cerebrovascular accident; HCVD, hypertensive
ystemic lupus erythematosus.
Table 4
Comparison of age, underlying conditions, vaccination status, and antiviral treatment among fatal cases of inﬂuenza B virus infection in Taiwan 2011–2012, by days from
onset to death
Days from
onset to
deatha
Number
of cases
Age, years Antiviral
treatment
received
Days to
starting antivirals
after onset
Vaccination With
underlying
diseases
Complications
18,
n (%)
65,
n (%)
Average Pulmonary
complication
Invasive
bacterial
infection
Neurological
complication
Myocarditis
or pericarditis
2–3 13 4 (36.3) 5 (11.1) 50.7 12 1–3 1 11 10 0 2 0
4–7 13 1 (9.1) 6 (13.3) 65.7 13 1–5 3 12 12 0 0 0
8–14 18 2 (18.2) 9 (20.0) 63.8 17 0–11 1 15 14 2 3 1
15–21 17 1 (9.1) 8 (17.8) 61.5 17 0–9 3 13 14 1 1 1
22–28 9 1 (9.1) 6 (13.3) 70.1 9 0–21 1 8 9 0 1 0
>29 17 2 (18.2) 11 (24.5) 68.9 17 0–13 2 15 15 2 0 0
Total 87 11 45 85 11 74 74 5 7 2
a Median/range days from onset to death, 14/2–52.
Table 5
Causes of death in the inﬂuenza B outbreak in Taiwan 2011–2012, by different age groups
Age, years Causes of death
Septic
shock
Pneumonia and
respiratory failure
Cardiopulmonary
failure
Pneumonia and
multiple organ failure
Central
failure
Hemorrhagic
stroke
Myocarditis Liver
failure
Cardiogenic
shock
0–4 0 0 3 0 0 0 0 0 0
5–18 1 1 2 2 1 0 1 0 0
25–49 1 1 0 1 0 1 1 0 0
50–64 15 4 3 3 0 0 0 1 0
65+ 18 17 3 5 0 0 0 0 2
Total 35 23 11 11 1 1 2 1 2
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most of the inﬂuenza B isolates in our study during the 2011–2012
season in Taiwan were Yamagata lineage group 2. Furthermore, we
found that viruses of phylogenetic group 2 have been isolated in
Taiwan since May 2007 and caused a small epidemic wave during
the 2007–2008 ﬂu season (Figure 1A; the predominant strain in the
2007–2008 season was A/Brisbane/59/07-like (H1N1)). The
nucleotide sequences coding for the HA proteins in the 2011–
2012 epidemic strains can be seen originating from the same
common ancestor as those of B/Florida/4/06, which was recom-
mend by the WHO for incorporation into the 2008–2009 inﬂuenza
vaccine. All 326 isolates showed 96.4–97.5% identity to the HA1
gene of the B/Florida vaccine strain, and viruses from group 2 share
3 amino acid changes, P108A, R48K, and T181A, with the B/Florida
vaccine strain. Most of the Taiwanese isolates in the present study
were found to have the signature amino acid change T181A in the
HA gene, along with R65H, T106I, and S295R in the NA gene, and
clustered in group 2, compared to the previous inﬂuenza B
epidemic strains in Taiwan (Figure 1B and Supplementary
Material Table S1).
4. Discussion
In this nationwide surveillance of case patients hospitalized
with inﬂuenza B virus infection during the 2011–2012 inﬂuenza
season, elderly people aged 65 years had the highest incidence
rate of hospitalization and death/hospitalization ratio. Risk factors
for severe illness in this outbreak were similar to those observed in
other countries,20–22 but with a higher prevalence of underlying
chronic medical conditions (76.7%). In addition, pneumonia is also
a commonly reported complication among patients hospitalized
with inﬂuenza B infection.
In the prior two inﬂuenza seasons in Taiwan, the main
circulating strains of inﬂuenza B belonged to the B/Victoria
lineage. However, the predominant inﬂuenza B viruses
circulating in the 2011–2012 season belonged to the B/Yamagatalineage (B/Wisconsin/1/2010); the B strain recommended for the
2011–2012 vaccine was B/Brisbane/60/2008, which derived from
B/Victoria lineage-like virus (B/Vic-like) (Supplementary Mate-
rial Table S2). The B/Vic-like vaccine antigen was not capable of
inducing a high level of protective immunity against heterologous
B/Yam-like circulating virus.23,24 The immune status of the
patient could be another factor predisposing to a severe outcome,
but we were unable to perform antibody responses tests, as serum
samples were not available for the patients in this study. A
combination of these two factors made it possible for this B/Yam
variant to become the predominant strain and cause the disease
outbreak. This provided an opportunity to investigate the link
between clinical and molecular epidemiologic characteristics in
high-risk populations. It is not clear whether the high mortality
and morbidity in this epidemic was due to a delay in testing,
ascertainment of results, or making antiviral treatment decisions.
However, conﬁrmation of cases in adults highlights the fact that
persons of any age can be infected. Persons who are at increased
risk of inﬂuenza complications (e.g., persons aged 18 or 65
years, those with hypertension or diabetes, immunocompromised
persons, and those with underlying chronic medical conditions)
who develop an inﬂuenza-like illness should see their health care
provider promptly to determine whether treatment with antiviral
medication is warranted.
Of note, most of the fatal cases in our study were infected with
group 2 viruses, whereas during the same time span, most strains
isolated worldwide were derived from group 3. According to the
phylogenetic data, most Taiwanese B/Yam-like viruses, and some
Japanese B/Yam-like viruses, fell into group 2; this is in contrast to
the situation in other Asian countries (e.g., China, Hong Kong,
Philippines, and Singapore) during the 2011–2012 season, in which
group 3 viruses were predominant (Figure 1B). These genetic
observations suggest a regional trend in B/Yam-like viruses and
indicate that new phylogenetic lineages and antigenic variants
emerging in neighboring countries were likely to be the progenitors
of the epidemic strains in the following seasons. Understanding
Figure 1. (A) Weekly inﬂuenza B activity and positive rates of Yamagata and Victoria lineage viruses in Taiwan from 1999 to 2012. (B) Phylogenetic relationships of the HA
gene segment of inﬂuenza B Yamagata virus sampled in Taiwan during 1999–2012, estimated using the maximum likelihood method. The tree was rooted on the oldest
isolates (B/Beijing/184/93). Bootstrap values (1000 replicates) >70% are shown for key nodes. Isolates of severe cases in the Taiwan 2011–2012 outbreak are shown in red, and
fatal cases are denoted with a capital F. Isolates from other Asian countries during the 2011–2012 ﬂu season are shown in green, and virus isolated in 1999–2011 are shown in
black.
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antigenic and genetic variants in regional areas may serve as a
warning system and may be important to predict the potential
emergence of new epidemic dominant strains.
Compared to inﬂuenza A viruses, inﬂuenza B viruses do not gain
as much attention because their ability to undergo antigenic shiftor antigenic drift occurs more slowly.9,10 Most of the clinical
isolates in our study did not react well (8- to 32-fold HI reduced
titers), suggesting that antigenic drift was occurring. However, the
HI antibody titers are considered to be protective (40) with
B/Florida/4/06-like, which was recommended by the WHO for
incorporation into the 2008–2009 Northern Hemisphere inﬂuenza
S.-C. Chiu et al. / International Journal of Infectious Diseases 23 (2014) 94–100 99vaccine.25 It is worth noting that an increasing number of B/Yam-
like isolates, as characterized in our report, have an additional
amino acid substitution T181A, which is in antigenic site D and
located at the bottom of the HA1 globular head.26,27 The new
genetic variants detected in group 2 are both genetically and
antigenically similar to those of the previous epidemic in 2007 in
Taiwan, but different  from the B/Florida-like vaccine strain. The
new variants react well with antisera against B/Wisconsin/1/
2010-like, which was the inﬂuenza B component recommended
for the 2012–2013 inﬂuenza vaccine. Thus, this type B variant
may represent a harbinger of the epidemic strain and may have
the capacity to become the dominant inﬂuenza B virus
worldwide. In fact, an epidemic of group 2 inﬂuenza B virus
was observed in the USA 4 months after the epidemic experi-
enced in Taiwan.28 These results demonstrate that the vaccine
strains recommended by the WHO were circulating in Taiwan
one to two inﬂuenza seasons earlier. The seasonal patterns
synchronized with genetic diversity of inﬂuenza B viruses
observed in Taiwan make it possible to capture the evolutionary
dynamics and epidemiological rules governing antigenic drift29
and may serve as an early warning system for the detection of an
emerging new epidemic strain.
In conclusion, the mismatch of inﬂuenza vaccination with the
inﬂuenza B outbreak in Taiwan does not imply that vaccination is
not an effective strategy for minimizing the infection. Because of
the continued co-circulation of two inﬂuenza B lineages, selecting
the best match for the annual inﬂuenza vaccine is difﬁcult. There is
the possibility that strategies for the control of inﬂuenza B virus
should be considered separately from those of inﬂuenza A virus,
or there should be ﬂexibility to revise the guidelines and
re-vaccinate populations in a timely manner to lessen the effect
of any outbreak, as and when the need arises. Moreover, the
preferential use of the new quadrivalent vaccines including an
inﬂuenza B strain of each lineage is likely to improve vaccine
protection. The WHO has made recommendations for inclusion of
a second inﬂuenza B vaccine virus in quadrivalent inﬂuenza
vaccines for the 2013–2014 season. The switch from trivalent to
quadrivalent is a viable alternative to inﬂuenza vaccination with
the possibility of eliminating inﬂuenza B lineage mismatch
between circulating inﬂuenza and the single B lineage. With this
kind of sustained partnership between local health departments
and their communities, along with access to active surveillance,
more people in the community are motivated to seek care,
resulting in a positive feedback cycle that can moderate the
morbidity and mortality and reduce the impact of inﬂuenza B
epidemics. Data presented here provide evidence that suggests
Taiwanese inﬂuenza B viruses were circulating ahead of the
recommendations for the inclusion of corresponding strains in the
seasonal inﬂuenza vaccine. These results facilitate a better
understanding of the severity of the inﬂuenza B epidemic in
Taiwan during the 2011–2012 season and will contribute to the
information on the clinical and epidemiological impact of
inﬂuenza B viruses.
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